Drug intelligence / Profile preview

T3011 + pembrolizumab

Development stage: Unknown
Lead developer: ImmVira
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

This combination involves **MVR-T3011**, an oncolytic virus product developed by ImmVira Pharma Co. Ltd., and **pembrolizumab**, a checkpoint inhibitor. MVR-T3011 is administered intratumorally and is being studied for its ability to modify the tumor microenvironment and enhance immune response. Pembrolizumab is an anti-PD-1 antibody that promotes immune response against cancer cells. The combination is being evaluated for safety and efficacy in treating advanced or metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC).

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on T3011 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T3011 + pembrolizumab.

Explore the full profile